Humacyte Stock News

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) --  Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facilit...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of Humacyte stockholders. Our investigation concerns whether Humacyte has violated the federal securities laws and/or engaged in other unlawful business practi...

SAN FRANCISCO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- On October 17, 2024, the U.S. Federal Food & Drug Administration (“FDA”) published its April 5, 2024 report addressed to Humacyte's Chief Operating Officer (Heather Prichard) detailing problems with Humacyte's facilities. The FDA's April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an earni...

Humacyte, Inc. (NASDAQ:HUMA ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen & Company Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Verno...

SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facility...

- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the  Treatment of Vascular Trauma is ongoing -

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors.

SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / On October 17, 2024, the U.S. Federal Food & Drug Administration ("FDA") published its April 5, 2024 report addressed to Humacyte's Chief Operating Officer (Heather Prichard) detailing problems with Humacyte's facilities. The FDA's April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an ea...